Indoco Remedies, recorded total revenue growth of 24.8 per cent at Rs 2023 million during the second quarter of FY 2013-14 as against Rs 1620.7 million during the same period last year. The company witnessed significant improvement in EBIDTA margins in this quarter. EBIDTA as a percentage to net sales is 18.9 per cent at Rs 368.5 million as against 15.9 per cent at Rs 261.3 million during the same period last year. Profit after tax is Rs 160.4 million as against Rs 120.8 million for the same period last year.
The un-audited results for the second quarter of the financial year 2013-14 were announced by the Board of Directors of Indoco Remedies at a recently held meeting held in Mumbai.
Suresh G Kare, Chairman, Indoco Remedies said, “The performance of our company across all segments has been good in the second quarter as seen from the improvement in top line as well as EBIDTA margins. With expected sales growth from regulated markets and resolution of issues related to implementation of new pricing policy in domestic markets, we are confident of maintaining the growth momentum in the coming quarters too.”
EP News Bureau – Mumbai
